Mikhail (Misha) V. Blagosklonny
Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny subsequently moved to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diversified biomedical topics, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
After authoring seven papers within the period of a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Mikhail Blagosklonny published a
Lot of experimental research papers and theoretical papers as sole
Writer. These sole-author articles
Included two crucial themes.
The first of these focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Validation their resistance. The outcomes and underlying
Notion were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the work was
Titled, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint publication in 2001.
The second topic throughout Dr. Blagosklonny’s sole-author publications
Is a research methodology to develop knowledge by
Bringing several facts together from seemingly unrelated areas.
This results in new concepts with testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Once again, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important result revealed by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others can’t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Stopping organism aging — in other words, “preventing cancer
Via remainng young. ” His lab closely worked together with
Andrei Gudkov’s and performed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of extra anti-aging drugs beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including a few models like
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence via rapamycin as well as other mTOR inhibitors, life
Extension and cancer stoppage in mice, and combinations of anti-
Aging drugs to be appliedamong humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.